undamentalytics Newsletter

Cronos Group Inc. income statement

In fiscal 2025, Cronos Group Inc. reported revenue of $147m, up 24.6% on the year before, operating income of −$17.4m (a -11.9% margin) and net income of −$9.4m, or −$0.02 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Cronos Group Inc.: income statement, annual
Fiscal year2017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue3122447658787118147179
Gross profit26−18−26−181512256382
Research and development02122022136445
Selling and marketing032334211823222224
General and administrative5138181916849474245
Operating income−6−20−153−219−292−111−85−77−17−2
Interest expense001000————
Provision for credit losses—00212−1−2−115—
Income before tax−2−211,166−73−129−121−7437−1768
Income tax−1001−034−3−3−14−11
Net income−1−221,167−73−396−169−7441−970
Diluted EPS−$0.01−$0.06$3.33−$0.21−$1.07−$0.45−$0.19$0.11−$0.02$0.18
Diluted shares (average)354m345m343m352m370m377m381m386m383m380m
EBITDA−5−19−149−212−277−98−77−67−36

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: CRON vs KMDAAMRN vs CRONBTMD vs CRONCRON vs OGI

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Cronos Group Inc.'s SEC filings (10-K and 10-Q), retrieved October 31, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Cronos Group Inc.